Cargando…

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis

BACKGROUND: The development of targeted therapies has created a pressing clinical need for molecular characterisation of cancers. In this retrospective study, high-resolution melting analysis (HRMA) was validated and implemented for screening of 164 colorectal cancer (CRC) patients to detect KRAS ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deschoolmeester, V, Boeckx, C, Baay, M, Weyler, J, Wuyts, W, Van Marck, E, Peeters, M, Lardon, F, Vermorken, J B
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990591/ https://www.ncbi.nlm.nih.gov/pubmed/20959826 http://dx.doi.org/10.1038/sj.bjc.6605959

Ejemplares similares

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Detection of HPV and the role of p16(INK4A )overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer
por: Deschoolmeester, Vanessa, et al.
Publicado: (2010)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
por: Benoy, I H, et al.
Publicado: (2006)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

Disseminated tumour cells as a prognostic biomarker in colorectal cancer
por: Flatmark, K, et al.
Publicado: (2011)

Expression and prognostic value of transcription factor PROX1 in colorectal cancer
por: Skog, M, et al.
Publicado: (2011)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer
por: Chen, Z-Y, et al.
Publicado: (2015)

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene
por: Mariani, Sara, et al.
Publicado: (2017)

Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer
por: Leitch, E F, et al.
Publicado: (2007)

The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis
por: Xing, X, et al.
Publicado: (2013)

Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia
por: Malesci, A, et al.
Publicado: (2014)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

Prognostic significance of CD44 variant 2 upregulation in colorectal cancer
por: Ozawa, M, et al.
Publicado: (2014)

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location
por: Bae, J M, et al.
Publicado: (2013)

Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer
por: Hector, S, et al.
Publicado: (2012)

Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer
por: Goossens-Beumer, I J, et al.
Publicado: (2014)

The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer
por: Talieri, M, et al.
Publicado: (2009)

A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer
por: Eberhard, J, et al.
Publicado: (2012)

CD133 expression is an independent prognostic marker for low survival in colorectal cancer
por: Horst, D, et al.
Publicado: (2008)

Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
por: Gordziel, C, et al.
Publicado: (2013)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e2ih1blgt8h073qdpkbghgljhh